$PGNY
Progyny, Inc.

2023 Q3 Form 10-Q Financial Statement

#000155130623000063 Filed on August 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $280.9M $279.4M
YoY Change 36.77% 43.27%
Cost Of Revenue $218.3M $218.7M
YoY Change 36.95% 44.74%
Gross Profit $62.62M $60.64M
YoY Change 36.15% 38.18%
Gross Profit Margin 22.29% 21.71%
Selling, General & Admin $44.44M $45.46M
YoY Change 27.91% 29.7%
% of Gross Profit 70.96% 74.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $500.0K $527.0K
YoY Change 23.46% 36.53%
% of Gross Profit 0.8% 0.87%
Operating Expenses $44.44M $45.46M
YoY Change 27.91% 29.7%
Operating Profit $18.19M $15.18M
YoY Change 61.61% 71.8%
Interest Expense $1.000M $706.0K
YoY Change 395.05% 1665.0%
% of Operating Profit 5.5% 4.65%
Other Income/Expense, Net $2.742M $1.983M
YoY Change 865.49% 2950.77%
Pretax Income $20.93M $17.17M
YoY Change 81.39% 92.82%
Income Tax $5.033M $2.176M
% Of Pretax Income 24.05% 12.68%
Net Earnings $15.90M $14.99M
YoY Change 20.34% 70.97%
Net Earnings / Revenue 5.66% 5.37%
Basic Earnings Per Share $0.17 $160.00
Diluted Earnings Per Share $0.16 $150.00
COMMON SHARES
Basic Shares Outstanding 95.41M shares 94.41M shares
Diluted Shares Outstanding 100.9M shares 100.6M shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $335.6M $282.5M
YoY Change 137.99% 130.82%
Cash & Equivalents $158.1M $170.6M
Short-Term Investments $177.5M $111.9M
Other Short-Term Assets $7.000M $13.68M
YoY Change 146.65% 231.24%
Inventory
Prepaid Expenses
Receivables $268.8M $265.0M
Other Receivables $0.00 $0.00
Total Short-Term Assets $611.3M $561.1M
YoY Change 52.11% 57.45%
LONG-TERM ASSETS
Property, Plant & Equipment $9.716M $9.497M
YoY Change 34.93% 51.32%
Goodwill $11.88M $11.88M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.589M $3.514M
YoY Change -13.02% -18.11%
Total Long-Term Assets $115.2M $120.4M
YoY Change 6.14% 13.06%
TOTAL ASSETS
Total Short-Term Assets $611.3M $561.1M
Total Long-Term Assets $115.2M $120.4M
Total Assets $726.5M $681.5M
YoY Change 42.33% 47.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $132.0M $130.2M
YoY Change 26.76% 40.48%
Accrued Expenses $61.40M $63.74M
YoY Change 16.5% 22.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $193.4M $193.9M
YoY Change 23.3% 33.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $17.70M $18.14M
YoY Change 163.39% 160.79%
Total Long-Term Liabilities $17.70M $18.14M
YoY Change 163.39% 160.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $193.4M $193.9M
Total Long-Term Liabilities $17.70M $18.14M
Total Liabilities $211.1M $212.0M
YoY Change 29.06% 39.63%
SHAREHOLDERS EQUITY
Retained Earnings $76.50M $60.60M
YoY Change 211.92% 435.6%
Common Stock $438.1M $408.8M
YoY Change 35.56% 35.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $515.4M $469.5M
YoY Change
Total Liabilities & Shareholders Equity $726.5M $681.5M
YoY Change 42.33% 47.24%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $15.90M $14.99M
YoY Change 20.34% 70.97%
Depreciation, Depletion And Amortization $500.0K $527.0K
YoY Change 23.46% 36.53%
Cash From Operating Activities $54.20M $76.01M
YoY Change 159.4% 294.95%
INVESTING ACTIVITIES
Capital Expenditures $1.000M $759.0K
YoY Change -180.65% -254.9%
Acquisitions
YoY Change
Other Investing Activities -$63.30M -$58.16M
YoY Change 9852.83% 7463.59%
Cash From Investing Activities -$64.30M -$58.92M
YoY Change 3327.51% 4580.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.300M -1.839M
YoY Change 87.3% -11.5%
NET CHANGE
Cash From Operating Activities 54.20M 76.01M
Cash From Investing Activities -64.30M -58.92M
Cash From Financing Activities -2.300M -1.839M
Net Change In Cash -12.40M 15.25M
YoY Change -169.7% -4.14%
FREE CASH FLOW
Cash From Operating Activities $54.20M $76.01M
Capital Expenditures $1.000M $759.0K
Free Cash Flow $53.20M $75.25M
YoY Change 140.35% 281.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://progyny.com/20230630#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://progyny.com/20230630#AccruedLiabilitiesAndOtherLiabilitiesCurrent
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
358000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
14991000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
469499000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
279619000 usd
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-1214000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
23822000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
376968000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-3565000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
62846000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
581000 usd
us-gaap Net Income Loss
NetIncomeLoss
32669000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
469499000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
251822000 usd
us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-3173000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48525000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
111000 usd
us-gaap Net Income Loss
NetIncomeLoss
13739000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
311024000 usd
us-gaap Profit Loss
ProfitLoss
32669000 usd
us-gaap Profit Loss
ProfitLoss
13739000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
824000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-5070000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1068000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
750000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
62561000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
48154000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9794000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
6097000 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
1324000 usd
us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
0 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34686000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
101405000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9189000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-421000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
20853000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
31075000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
13829000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
15591000 usd
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
-581000 usd
us-gaap Increase Decrease In Other Noncurrent Assets And Liabilities Net
IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
1368000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
96973000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
7984000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2010000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1280000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
120599000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
94611000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
79813000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
55074000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42796000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40817000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3124000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1209000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7426000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5635000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
617000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
576000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3685000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-3850000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
50492000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36683000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
120078000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91413000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
170570000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54730000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
698000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
60000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
438000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
303000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP generally requires management to make estimates and assumptions that affect the reported amount of certain assets, liabilities, revenue, and expenses, and the related disclosure of contingent assets and liabilities. Such estimates include, but are not limited to, the determination of accrued receivables related to revenue recognition, accrued claims payable, allowance for doubtful accounts, stock-based compensation expense, lease liabilities, and accounting for income taxes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div>
pgny Revenue From Contract With Customer Term
RevenueFromContractWithCustomerTerm
P3Y
pgny Revenue Remaining Performance Obligation Remaining Contract Term
RevenueRemainingPerformanceObligationRemainingContractTerm
P1Y
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18451000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6903000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1451000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1231000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18138000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6482000 usd
CY2023Q2 pgny Accrued Receivables
AccruedReceivables
61300000 usd
CY2022Q4 pgny Accrued Receivables
AccruedReceivables
54600000 usd
CY2023Q2 pgny Accrued Claims Payable Current
AccruedClaimsPayableCurrent
42000000 usd
CY2022Q4 pgny Accrued Claims Payable Current
AccruedClaimsPayableCurrent
31100000 usd
pgny Claims Payable Payment Period
ClaimsPayablePaymentPeriod
P30D
CY2023Q2 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
45500000 usd
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
42900000 usd
pgny Unbilled Receivables Billed To Customers Period
UnbilledReceivablesBilledToCustomersPeriod
P30D
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
9794000 usd
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
230000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
37892000 usd
pgny Cost Of Goods And Service Sold Specialty Pharmacies Contract Term
CostOfGoodsAndServiceSoldSpecialtyPharmaciesContractTerm
P1Y
pgny Billing Terms
BillingTerms
P20D
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
279373000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
195004000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
537767000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
367221000 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
600000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
600000 usd
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0459
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0429
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
643000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2250000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2793000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2793000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2793000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13641000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
24913000 usd
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5324000 usd
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
19589000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
18138000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31753000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23654000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62561000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48154000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14991000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8768000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
32669000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13739000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94738651 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91964978 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94290653 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91578707 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
160
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
350
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
14991000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
8768000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
32669000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
13739000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94738651 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91964978 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94290653 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91578707 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
5877268 shares
CY2022Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7707791 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
6100920 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8146857 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100615919 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99672769 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
100391573 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
99725564 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
150
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
330
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13041906 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9567223 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13353471 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9194237 shares
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001551306-23-000063-index-headers.html Edgar Link pending
0001551306-23-000063-index.html Edgar Link pending
0001551306-23-000063.txt Edgar Link pending
0001551306-23-000063-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pgny-20230630.htm Edgar Link pending
pgny-20230630.xsd Edgar Link pending
pgny-20230630xex311.htm Edgar Link pending
pgny-20230630xex312.htm Edgar Link pending
pgny-20230630xex321.htm Edgar Link pending
pgny-20230630xex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pgny-20230630_cal.xml Edgar Link unprocessable
pgny-20230630_def.xml Edgar Link unprocessable
pgny-20230630_lab.xml Edgar Link unprocessable
pgny-20230630_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pgny-20230630_pre.xml Edgar Link unprocessable